Remote monitoring platform for people with advanced chronic kidney disease
Tests a virtual care platform added to usual care in adults with advanced kidney disease.
Plain-language title generated from the registry record
Registry title: CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
Key facts
- Where
- London, Scarborough Village, and Winnipeg, CanadaSee the 5 sites
Where in Canada
- London Health Sciences CentreLondon, CanadaTaking people
- Scarborough Health Network - General HospitalScarborough Village, CanadaTaking people
- Chronic Disease Innovation Centre, Seven Oaks HospitalWinnipeg, CanadaTaking people
- Health Sciences CentreWinnipeg, CanadaTaking people
- St. Boniface HospitalWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Manitoba
- Trial code
- NCT05726526
- Record updated
- 10 September 2026
- Original description
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.Read full original descriptionShow less
A Pragmatic Randomized Controlled Trial of a CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.
Inclusion: >18 years of age; Patient or primary caregiver can read and speak English; Patient or patients substitute decision maker is able to provide informed consent; Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.); Have stage 5 CKD (2 measurements of eGFR <15ml/min/1.73m2); eGFR will be calculated with the CKD-EPI equation, or have >40% chance of beginning dialysis in the next 2 years based on the Kidney Failure Risk Equation; Followed in a multidisciplinary CKD clinic.
Exclusion: Inability of self or caregiver assisted self-monitoring using VIEWER.